Drug or intervention
Lenalidomide Clinical Trials
Studies that test Lenalidomide, alone, with other treatments or as the comparison.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 222Multiple Myeloma
A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant
Elranatamab is a bispecific antibody: binding of elranatamab to CD3-expressing T-cells and BCMA-expressing multiple myeloma cells causes targeted T-cell-mediated cytotoxicity.
- Trial name
- MagnetisMM-6 (NCT05623020)
- Testing
- Elranatamab, Daratumumab, Lenalidomide
- Where
- 180 sites in United States, Argentina and 23 more
- Volunteers
- 1,060 people
- Sponsor
- Pfizer
Newly Diagnosed Multiple Myeloma (NDMM)
Less Doses of Daratumumab Are Adequate to Achieve Response in Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether a modified (less frequent) dosing schedule of daratumumab, when added to standard VRd therapy, can be an effective induction regimen for treating newly diagnosed multiple…
- Trial name
- NCT07891923
- Testing
- Daratumumab (Intravenously), Bortezomib (BTZ), Len (lenalidomide)
- Where
- 2 sites in India
- Volunteers
- 52 people
- Sponsor
- Tata Memorial Centre
Plasma Cell Leukemia
Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial
This phase II trial compares standard consolidation with daratumumab, carfilzomib, lenalidomide, and dexamethasone to consolidation with teclistamab following standard induction therapy and autologous hematopoietic stem cell…
- Trial name
- NCT07605416
- Testing
- Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration
- Where
- 11 sites in United States
- Volunteers
- 74 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma.
- Trial name
- NCT04822337
- Testing
- Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Wake Forest University Health Sciences
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma
This phase I trial studies the side effects and best dose of mosunetuzumab when given together with polatuzumab vedotin and lenalidomide in treating patients with diffuse large B-cell lymphoma (DLBCL) that has come back after a…
- Conditions
- Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
- Trial name
- NCT06015880
- Testing
- Biospecimen Collection, Computed Tomography, Lenalidomide
- Where
- 8 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
The goal of this clinical trial is to evaluate whether CM336, a BCMA/CD3 bispecific antibody, in combination with daratumumab and lenalidomide can induce deep and durable responses in adults with transplant-ineligible newly…
- Trial name
- CAREMM-010 (NCT07830485)
- Testing
- CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma
This phase I/II trial tests the safety and effectiveness of glofitamab (with obinutuzumab pretreatment), venetoclax, and lenalidomide in treating patients with newly diagnosed, high risk mantle cell lymphoma.
- Conditions
- Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma
- Trial name
- NCT05861050
- Testing
- Biopsy, Biospecimen Collection, Bone Marrow Biopsy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- City of Hope Medical Center
Multiple Myeloma, Plasma Cell Leukemia
Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma
Historically, the frailest patients with multiple myeloma are under-represented in clinical trials, and have very high rates of treatment discontinuation, and early treatment mortality.
- Trial name
- UltraFrailMM (NCT06517017)
- Testing
- Isatuximab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- University of Utah
Multiple Myeloma (MM)
Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma
This phase II/III trial compares the usual treatment (daratumumab and hyaluronidase, lenalidomide, bortezomib and dexamethasone [DaraRVd] regimen followed by autologous stem cell transplant [ASCT] followed by maintenance therapy)…
- Trial name
- NCT07887984
- Testing
- Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib
- Volunteers
- 920 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Newly Diagnosed Multiple Myeloma
A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma
The goal of this clinical study iMMagine-4 is to compare and assess the safety and effectiveness of anitocabtagene autoleucel versus standard of care therapy (SOCT) in participants with newly diagnosed multiple myeloma (NDMM) who…
- Trial name
- iMMagine-4 (NCT07887672)
- Testing
- Anitocabtagene autoleucel, Daratumumab, Bortezomib
- Volunteers
- 600 people
- Sponsor
- Kite, A Gilead Company
Completed, with results posted
All 285Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies
Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies
Background: Mature T-cell malignancies (TCMs) are a rare group of cancers that usually do not have effective treatments or cures. Because of this, participants with TCMs often relapse and have a poor overall prognosis.
- Conditions
- Cutaneous T-Cell Lymphoma, Mature T-cell Malignancies, Peripheral T-Cell Lymphoma, Relapsed/ Refractory T-cell Malignancies
- Trial name
- NCT04447027
- Testing
- Romidepsin, Lenalidomide, CC-486 (5-azacitidine)
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) [Car-BiRD] Therapy for Subjects With Multiple Myeloma
The purpose of this study is to evaluate the safety and effectiveness of an investigational new drug called carfilzomib, in combination with dexamethasone in subjects with newly diagnosed multiple myeloma followed by treatment…
- Trial name
- CarBiRD (NCT01559935)
- Testing
- carfilzomib, Dexamethasone, Clarithromycin
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- Weill Medical College of Cornell University
Plasma Cell Myeloma, Transplant-Related Carcinoma
Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma
This phase II trial studies the safety of alternating ixazomib citrate and lenalidomide as treatment to help keep cancer from coming back after stem cell transplant (maintenance therapy) in treating patients with multiple…
- Trial name
- NCT02619682
- Testing
- Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma
Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma
This is a Phase II study of daratumumab based therapies for older adults with multiple myeloma.
- Trial name
- NCT04151667
- Testing
- Daratumumab Injection, Dexamethasone Oral, Lenalidomide Pill
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma
Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma
This phase II trial studies how well brentuximab vedotin and lenalidomide work in treating patients with stage IB-IVB T-cell lymphoma that have come back or do not respond to treatment.
- Conditions
- Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma
- Trial name
- NCT03409432
- Testing
- Brentuximab Vedotin, Laboratory Biomarker Analysis, Lenalidomide
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- John Reneau